470 related articles for article (PubMed ID: 33027809)
21. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
Anderson MA; Tam C; Lew TE; Juneja S; Juneja M; Westerman D; Wall M; Lade S; Gorelik A; Huang DCS; Seymour JF; Roberts AW
Blood; 2017 Jun; 129(25):3362-3370. PubMed ID: 28473407
[TBL] [Abstract][Full Text] [Related]
22. Venetoclax in Relapsed or Refractory Hairy-Cell Leukemia.
Tiacci E; De Carolis L; Santi A; Falini B
N Engl J Med; 2023 Mar; 388(10):952-954. PubMed ID: 36884329
[No Abstract] [Full Text] [Related]
23. Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Cramer P; Tausch E; von Tresckow J; Giza A; Robrecht S; Schneider C; Fürstenau M; Langerbeins P; Al-Sawaf O; Pelzer BW; Fink AM; Fischer K; Wendtner CM; Eichhorst B; Kneba M; Stilgenbauer S; Hallek M
Blood; 2021 Nov; 138(19):1805-1816. PubMed ID: 34086865
[TBL] [Abstract][Full Text] [Related]
24. Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.
Wierda WG; Byrd JC; Davids MS; Furman RR; Cheson BD; Barr PM; Eradat H; Heffner L; Zhou L; Verdugo M; Potluri J; Choi M
Br J Haematol; 2019 Jun; 185(5):961-966. PubMed ID: 30478940
[No Abstract] [Full Text] [Related]
25. Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.
Rogers KA; Huang Y; Ruppert AS; Abruzzo LV; Andersen BL; Awan FT; Bhat SA; Dean A; Lucas M; Banks C; Grantier C; Heerema NA; Lozanski G; Maddocks KJ; Valentine TR; Weiss DM; Jones JA; Woyach JA; Byrd JC
J Clin Oncol; 2020 Nov; 38(31):3626-3637. PubMed ID: 32795224
[TBL] [Abstract][Full Text] [Related]
26. Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients.
Ferrarini I; Gandini F; Zapparoli E; Rigo A
Curr Oncol; 2022 Apr; 29(4):2792-2797. PubMed ID: 35448201
[TBL] [Abstract][Full Text] [Related]
27. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
[TBL] [Abstract][Full Text] [Related]
28. Venetoclax Data Prompt Rethink of CLL Therapy.
Cancer Discov; 2018 Mar; 8(3):OF5. PubMed ID: 29382644
[TBL] [Abstract][Full Text] [Related]
29. Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p).
Lacerda MP; Guedes NR; Yamakawa PE; Pereira AD; Fonseca ARBMD; Chauffaille MLLF; Goncalves MV; Yamamoto M; Rodrigues CA
Ann Hematol; 2017 Sep; 96(9):1577-1578. PubMed ID: 28597168
[No Abstract] [Full Text] [Related]
30. Upfront therapy: the case for continuous treatment.
Tam CS
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):55-58. PubMed ID: 34889433
[TBL] [Abstract][Full Text] [Related]
31. Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations.
Levin MD; Kater AP; Mattsson M; Kersting S; Ranti J; Thi Tuyet Tran H; Nasserinejad K; Niemann CU
BMJ Open; 2020 Oct; 10(10):e039168. PubMed ID: 33060089
[TBL] [Abstract][Full Text] [Related]
32. Impact of targeted agents on survival of chronic lymphocytic leukemia patients age >65 relative to age- and sex-matched population.
Molica S; Shanafelt TD; Allsup D; Giannarelli D
Am J Hematol; 2024 Mar; 99(3):480-483. PubMed ID: 38100222
[TBL] [Abstract][Full Text] [Related]
33. Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?
Smolej L
Br J Haematol; 2021 May; 193(4):723-726. PubMed ID: 33216352
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.
İskender G; İskender D; Ertek M
Turk J Haematol; 2020 Aug; 37(3):208-209. PubMed ID: 32248674
[No Abstract] [Full Text] [Related]
35. Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.
Molica S; Giannarelli D; Baumann T; Montserrat E
Eur J Haematol; 2020 May; 104(5):512-515. PubMed ID: 31957067
[No Abstract] [Full Text] [Related]
36. GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia.
Rogers KA
Lancet Oncol; 2024 Jun; 25(6):685-687. PubMed ID: 38821078
[No Abstract] [Full Text] [Related]
37. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.
Thijssen R; Slinger E; Weller K; Geest CR; Beaumont T; van Oers MH; Kater AP; Eldering E
Haematologica; 2015 Aug; 100(8):e302-6. PubMed ID: 25957396
[No Abstract] [Full Text] [Related]
38. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
Molica S; Gianfelici V; Levato L
Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
[No Abstract] [Full Text] [Related]
39. Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.
Molica S; Baumann T; Giannarelli D
Eur J Haematol; 2021 Mar; 106(3):425-427. PubMed ID: 33190324
[No Abstract] [Full Text] [Related]
40. Ibrutinib: searching for a partner drug.
Kater AP; Brown JR
Lancet Oncol; 2019 Jan; 20(1):3-5. PubMed ID: 30522966
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
